Organization
Istituto Oncologico Veneto IRCCS
11 clinical trials
3 abstracts
Abstract
Prognosis and tumor-infiltrating lymphocytes (TILs) in estrogen receptor (ER)-low metastatic breast cancer (MBC): Analysis from a large multi-institutional cohort and the TONIC phase II trial with nivolumab.Org: University of Padova, Istituto Oncologico Veneto IRCCS, Fondazione IRCCS INT, Milan, Italy, Netherlands Cancer Institute, University Hospital of Modena,
Abstract
Association of tumor-infiltrating lymphocytes (TILs) and immune signatures with PAM50 intrinsic subtyping hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (BC): A translational analysis of two multicentric neoadjuvant trials.Org: University of Padua School of Medicine, University of Padova, Veneto Institute of Oncology IOV-IRCCS, Reveal Genomics Srl, Istituto Oncologico Veneto IRCCS,
Abstract
A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy.Org: Department of Surgery Oncology and Gastroenterology, University of Padua, Padova, MO, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, IOV - Istituto Oncologico Veneto IRCCS -IOV, Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy, Azienda Unità Sanitaria Locale-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Reggio Emilia, Italy, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom,
Clinical trial
TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES). Phase II Clinical Trial, Single Arm, Two StageStatus: Terminated, Estimated PCD: 2017-02-21
Clinical trial
Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab: A Phase III Randomized Trial. Sponsor: Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche, Università di PadovaStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma: Observational StudyStatus: Active (not recruiting), Estimated PCD: 2023-06-26
Clinical trial
First Line Osimertinib in the Real World: an Inter-regional Prospective Study: FLOWERStatus: Completed, Estimated PCD: 2022-06-01
Clinical trial
Regorafenib in Relapsed Glioblastoma. An Observational, Multicentric and Prospective Study. IOV-GB-1-2020 REGOMA-OSSStatus: Completed, Estimated PCD: 2023-12-31
Clinical trial
Phase II Study of Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed as Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)Status: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
Regorafenib in Combination With Temozolomide With or Without Radiotherapy in Patients With Newly Diagnosed MGMT-Methylated, IDH Wild-type Glioblastoma. A Phase I Dose-finding StudyStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Regorafenib for Recurrent Grade 2 and 3 Meningioma. A Multicenter, Randomized Phase II Study (MIRAGE Trial)Status: Not yet recruiting, Estimated PCD: 2026-12-01
Clinical trial
Pure Florid and Pleomorphic Lobular Carcinoma in Situ of the Breast: Towards an Increasingly Uniform Management. A Multicenter Observational Retrospective Study.Status: Recruiting, Estimated PCD: 2024-04-30
Clinical trial
First-line Combination of Capecitabine and Oxaliplatin + Bevacizumab in Elderly Patients With Metastatic Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
The METROPHOLYS Study Metronomic Cyclophosphamide vs Doxorubicin in Elderly Patients With Advanced Soft Tissue Sarcomas Randomized, Controlled Open Label Clinical TrialStatus: Terminated, Estimated PCD: 2024-05-23